Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • temozolomide • albumin-bound paclitaxel • cyclophosphamide • dacarbazine • Amtagvi (lifileucel) • relatlimab (BMS-986016) • anzutresgene autoleucel (IMA203)

ML41701: A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors. (clinicaltrials.gov)

P2, N=22, Completed, National Taiwan University Hospital | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Feb 2026 | Trial primary completion date: Dec 2024 --> Feb 2026

1 day ago

Trial completion • Trial completion date • Trial primary completion date • IO biomarker

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I

Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • pemetrexed

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca (clinicaltrials.gov)

P2, N=46, Active, not recruiting, Virginia Commonwealth University | Trial completion date: Mar 2026 --> Mar 2027

1 day ago

Trial completion date • Checkpoint inhibition • IO biomarker

HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)

HR positive • HER-2 negative • HR negative • HER-2 negative + HR negative

Keytruda (pembrolizumab) • carboplatin • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • decitabine

NIBCUN: Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC (clinicaltrials.gov)

P2, N=36, Recruiting, Sun Yat-sen University | Trial completion date: Dec 2026 --> Dec 2029 | Trial primary completion date: Dec 2025 --> Dec 2029

1 day ago

Trial completion date • Trial primary completion date

Avastin (bevacizumab) • carboplatin • Tyvyt (sintilimab) • pemetrexed

BEATcc: Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix (clinicaltrials.gov)

P3, N=410, Completed, Grupo Español de Investigación en Cáncer de Ovario | Active, not recruiting --> Completed

1 day ago

Trial completion

Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • paclitaxel

Endometrial Neuroendocrine Carcinoma With Widespread Metastases: Diagnostic and Therapeutic Challenges in a Rare Malignancy. (PubMed, Cureus)

She underwent urgent T1 laminectomy with C5-T3 fusion, followed by systemic therapy with carboplatin/paclitaxel plus pembrolizumab, and later transitioned to carboplatin/etoposide. Histopathology confirmed small-cell NEC with squamous differentiation; expert review favored a poorly differentiated/dedifferentiated endometrial carcinoma with neuroendocrine and squamoid features. This case illustrates an atypical initial presentation with neurologic deficits from spinal metastases, emphasizing the need for prompt recognition and multidisciplinary management.

2 days ago

Journal • PD(L)-1 Biomarker

MUC16 (Mucin 16, Cell Surface Associated)

Keytruda (pembrolizumab) • carboplatin • paclitaxel • etoposide IV

Systemic AL (λ) Amyloidosis Discovered After Neoadjuvant Pembrolizumab-Based Chemoimmunotherapy for Resectable NSCLC: Case Report. (PubMed, Respirol Case Rep)

We report a 69-year-old man with resectable stage IIB right upper lobe lung adenocarcinoma who received neoadjuvant pembrolizumab, carboplatin, and pemetrexed followed by robotic-assisted lobectomy. He received adjuvant pembrolizumab and daratumumab-CyBorD with partial hematologic response. This case highlighted that amyloid can unexpectedly be a second diagnosis after post-neoadjuvant lung resections and that proteomic subtyping is essential for prompt haematologic staging and treatment.

2 days ago

Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • PTPRT (Protein tyrosine phosphatase receptor type T)

TP53 mutation • TMB-H

Keytruda (pembrolizumab) • carboplatin • pemetrexed • Darzalex (daratumumab)

Eprenetapopt in combination with carboplatin in high-grade ovarian and triple negative breast cancer cell lines with acquired resistance to olaparib. (PubMed, Front Oncol)

Combining eprenetapopt with carboplatin shows promising preclinical efficacy by enhancing cytotoxicity in olaparib-resistant models and demonstrating synergistic interaction; these data support the combination as a potential strategy to mitigate PARPi resistance and carboplatin cross-resistance in TP53 mutant HGSOC and TNBC cell lines. Although further studies are needed to elucidate the molecular mechanisms underlying the synergistic effect, here we point out the combination of eprenetapopt and carboplatin as a potential therapeutic strategy to address olaparib resistance in HGSOC and TNBC patients.

2 days ago

Preclinical • Journal • BRCA Biomarker • PARP Biomarker

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ANXA5 (Annexin A5)

TP53 mutation • BRCA2 mutation • BRCA1 mutation • HRD • TP53 wild-type

Lynparza (olaparib) • carboplatin • eprenetapopt (APR-246)

Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer (clinicaltrials.gov)

P=N/A, N=28, Not yet recruiting, Tang-Du Hospital

2 days ago

New trial

carboplatin • albumin-bound paclitaxel • pemetrexed • Qibeian (iparomlimab/tuvonralimab)

TROY: Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy (clinicaltrials.gov)

P2, N=116, Recruiting, Yonsei University | Not yet recruiting --> Recruiting

2 days ago

Enrollment open

HER-2 (Human epidermal growth factor receptor 2)

HER-2 expression

Avastin (bevacizumab) • carboplatin • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki)